News Archive - MELGEN

NewsJanuary 14, 2019

Introducing Dr Renata Varaljai and Dr Rohit Thakur…

It is with great pride that we can announce that the first two of the MELGEN early stage researchers have successfully completed their PhD studies and passed their PhD Dissertation (also known as a Thesis) defence interviews (referred to in the UK as a Viva). Dr Renata Veraljai wasRead More

NewsSeptember 28, 2018

MELGEN at the European Researchers’ Night 2018!

European Researchers’ Night is an annual open science initiative that occurs in September which is dedicated to bringing popular science and the work of scientists into the general public. Over the course of two days, there are several events that are organized across Europe which help to interact andRead More

NewsSeptember 19, 2018

New Cancer Progress Report 2018 from AACR

The AACR (American Association of Cancer Research) has just released a new Cancer Progress Report for 2018. This report not only takes about straight science, but easily explains the basis of cancer development, summaries the risk factors and talks about what is the future of cancer research. The report alsoRead More

NewsSeptember 11, 2018

SMR2018 in Manchester: MELGEN will be there!

Most of the PhD students from the MELGEN will take part in the 15th International Congress of the Society for Melanoma Research. It will take place in Manchester, England, October 24-27, 2018. The Society for Melanoma Research 2018 Congress is a global meeting where melanoma experts, both clinicians andRead More

NewsAugust 29, 2018

Latest melanoma drug approvals: adjuvant dabrafenib plus trametinib

New drug combination: adjuvant dabrafenib plus trametinib for BRAF-mutant stage III melanoma The European Commission approved the combination of dabrafenib plus trametinib (Tafinlar® and Mekinist® by Novartis) for the adjuvant therapy of complete surgically resected stage III melanoma patients with BRAFV600 mutation. The dual targeting of the hyper-activated MAPKRead More

NewsAugust 21, 2018

Newly developed prediction tool to help understanding if patients will respond to Checkpoint Inhibitors

IMPRES, which stands for immuno-predictive score, is a newly created predictor of Immune Checkpoint Blockade (ICB) response for melanoma patients. ICB has been very successful in treatment of melanoma patients, however, only in a percentage of them. It is therefore important to understand who is likely to respond toRead More

NewsJuly 1, 2018

Latest melanoma drug approvals: encorafenib plus binimetinib

New drug combination: encorafenib plus binimetinib for BRAF-mutant metastatic melanoma Another milestone in the treatment of BRAFV600-mutant metastatic melanoma was marked by the newly approved drug combination of encorafenib plus binimetinib [Braftovi and Mektovi, by Array BioPharma Inc; approved by U.S. Food & Drug Administration (FDA) on June 27,Read More

NewsJune 1, 2018

MELGEN group leader Dr. David Adams elected as Fellow of the Academy of Medical Sciences

Congratulations to Dr. David Adams for his well-deserved election to the Academy of Medical Sciences (F.Med.Sci). Dr. David Adams was elected as one of 48 Fellows to join the highly prestigious academy, which includes senior researchers and academics from across the medical sciences and industry. About the fellowship TheRead More

NewsOctober 20, 2017

Lifetime Achievement Award for MELGEN Principal Coordinator at SMR Congress 2017

It has been an excellent Society for Melanoma Research (SMR) Congress for MELGEN this year. The 14th International Congress of the Society for Melanoma Research which this year was a joint meeting with the 9th World Congress of Melanoma was held in Brisbane, Australia, from 18th to the 21stRead More